Genome sequencing is becoming part of routine healthcare because it can answer clinical questions that single-gene tests may not address. It can support faster diagnosis, more informed treatment decisions, and clearer discussions around inherited risk.
For procurement and laboratory teams, the key challenge is choosing the right sequencing approach, validating quality, and managing sensitive data responsibly. This guide explains the essentials to review before signing a contract or building an in-house pipeline.
What Genome Sequencing Means in Day-To-Day Lab Terms
A genome is the full DNA instruction set within a cell. Genome sequencing reads the order of bases (A, C, G and T) across a defined region and compares the result with a reference to identify variants. In a hospital laboratory environment, the end-to-end process of generating results, validating quality, and translating variants into clinically useful findings is often described as genomic intelligence.
In clinical workflows, sequencing commonly supports:
- Diagnosis of unexplained symptoms
- Risk assessment and prevention planning for inherited diseases
- Therapy decisions, especially in oncology and pharmacogenomics
Why Genome Sequencing Adoption Is Rising in India
Sequencing demand is increasing because a single test can examine multiple targets and may reduce diagnostic delays for selected patient groups. It is commonly used for:
- Rare disease and paediatric genetics
- Hereditary cancer testing and tumour profiling
- Carrier screening and reproductive genetics
- Selected infectious disease surveillance
Next-Generation Sequencing and the Main Test Options
Most clinical programs rely on next-generation sequencing (NGS), which reads millions of DNA fragments in parallel and reconstructs the results through software. The main decision is how much DNA the test needs to analyse
1. Next-Generation Sequencing (NGS)
- NGS reads millions of DNA fragments at the same time.
- Software combines the data to analyze genetic information quickly.
- Hospitals and labs use it for disease diagnosis, precision medicine, and research.
Main Test Options
2. Whole Genome Sequencing (WGS)
What it covers
- Analyzes almost the entire genome (all DNA).
Best suited for
- Complex or unclear medical cases.
- Broad genetic investigations.
Key trade-off
- Produces huge amounts of data.
- Requires more storage, analysis time, and interpretation expertise.
3. Whole Exome Sequencing (WES)
What it covers
- Focuses only on protein-coding regions (exons).
Best suited for
- Many rare disease diagnoses.
- Faster and lower-cost analysis compared to WGS.
Key trade-off
- Can miss important mutations outside coding regions.
4. Targeted Gene Panels
What it covers
- Examines selected genes linked to specific diseases.
Best suited for
- Focused clinical questions such as cancer panels or inherited disorders.
Key trade-off
- Limited to the genes included in the panel design.
Simple Comparison
- WGS = Most comprehensive, highest data volume.
- WES = Balanced approach for many clinical cases.
- Targeted Panels = Fast and focused testing for known conditions.
A useful procurement principle is to align test breadth with the clinical question and urgency. Panels can be faster for narrow indications, whereas broader questions often favour exome or whole-genome sequencing.
From Sample to Report: The Workflow You Are Buying
A typical sequencing workflow includes:
- Pre-analytical steps: consent, identity checks, sample choice (blood, saliva or tissue), and transport stability
- Wet laboratory processing: DNA extraction, library preparation, and target enrichment, where applicable
- Sequencing: run controls, demultiplex reads, and generate FASTQ files
- Bioinformatics: align reads, call variants, annotate findings, interpret results, and generate the report
Quality Metrics to Include in Vendor Evaluations
Ask vendors to share typical QC ranges and failure thresholds, not only marketing claims. Common quality markers include:
- Read quality and per-base quality scores
- Depth and breadth of coverage across clinically important regions
- Contamination checks and sample swap controls
- Percentage of targets meeting minimum coverage
These metrics affect whether variants can be detected confidently or may be missed.
NGS Sequencing Data Analysis and Dna Sequence Analysis in Practice
Sequencing outcomes depend as much on the analysis pipeline as on the instrument. NGS sequencing data analysis is usually described across three layers:
| Layer | Output | What you should verify |
| Primary | FASTQ files and run QC | Transparent run pass, or fail rules |
| Secondary | BAM or CRAM files, plus VCF | Coverage, mapping, and variant-calling performance |
| Tertiary | Interpreted report | Evidence trail and consistent variant classification |
DNA sequence analysis also includes clinical interpretation. Reports should state which variant types are assessed, what the test limitations are, and how uncertain findings are handled.
What a Clinical Report Should Include
Your procurement specification can require each clinical report to include:
- Patient identifiers and clinical indication
- Assay type, reference genome build, and coverage summary
- Reported variants with supporting evidence and classification
- Clear next steps, such as confirmatory testing and genetic counselling, when appropriate
- Plain-language limitations, including regions with low coverage and variant types outside the scope
If you are outsourcing, ask whether raw data is returned, how long it is retained, and how reanalysis requests are handled.
Procurement Due Diligence: Questions That Prevent Surprises
A structured evaluation keeps discussions aligned across clinicians, laboratory operations, IT, and compliance teams. Focus on:
- Clinical fit: supported indications and when each test type is recommended
- Turnaround time: routine loads, peak loads, reruns, and reporting timelines
- Validation: controls and proficiency testing approach
- Reporting: clarity, clinical relevance, and communication of limitations
- Service: SLAs, training, and supply continuity
- Cost: per-sample charges, storage costs, and reanalysis expenses
Plan clinician training early, as report interpretation workflows may change and need clear internal ownership.
Use a simple comparison grid during vendor evaluation.
| Area | What to ask | What to request |
| Performance | Coverage targets and rerun policy | QC dashboards and example runs |
| Scope | Variant types included | Technical note and sample reports |
| Data security | Encryption, access controls, and audit trails | Security policy summary |
| Quality systems | Accreditation scope | NABL and ISO certificates, where applicable |
Data Governance Essentials for Indian Healthcare
Genetic data can identify a person and may also have implications for relatives. Put governance controls in place early:
- Obtain explicit consent for storage and reanalysis
- Set retention and deletion rules aligned with hospital policy
- Restrict access by role and maintain audit logs
- Ensure data processing aligns with India's Digital Personal Data Protection Act, 2023, including principles for lawful use and security safeguards
FAQs
1.) Is genome sequencing the same as a genetic test?
Genetic testing includes many methods. Genome sequencing is one method that reads DNA at scale, while other tests may target a single gene, a few variants, or chromosome-level changes.
2.) When should a hospital consider whole genome sequencing?
A hospital may consider whole-genome sequencing when the clinical picture is unclear, earlier tests have not provided an answer, or structural and non-coding variants may be relevant. Targeted panels can be more efficient when the indication is clearly defined.
3.) What drives turnaround time in genome sequencing programs?
Turnaround time depends on sample logistics, batching strategy, reruns for low coverage, and the time needed for clinical interpretation and report sign-out. Clear QC rules can support more predictable timelines.
4.) What should be documented for NGS sequencing data analysis in audits?
Audit documentation should include pipeline versions, validation results, QC thresholds, change logs, checks used to approve or reject samples, and a traceable report sign-out.
